Articles on this Page
- 11/03/16--16:59: _Comment on MedCrave...
- 11/03/16--17:03: _Comment on Beall’s ...
- 11/04/16--06:08: _Comment on MedCrave...
- 11/04/16--06:12: _Comment on Beall’s ...
- 11/04/16--06:16: _Comment on Beall’s ...
- 11/04/16--07:08: _Comment on MedCrave...
- 11/04/16--07:23: _Comment on Beall’s ...
- 11/04/16--07:48: _Comment on MedCrave...
- 11/04/16--08:33: _Comment on Two OA J...
- 11/04/16--10:08: _Comment on Beall’s ...
- 11/04/16--10:20: _Comment on MedCrave...
- 11/04/16--11:41: _Comment on Beall’s ...
- 11/05/16--05:56: _Comment on Beall’s ...
- 11/05/16--06:30: _Comment on About Th...
- 11/05/16--09:41: _Comment on Beall’s ...
- 11/05/16--09:45: _Comment on Beall’s ...
- 11/05/16--09:49: _Comment on Beall’s ...
- 11/05/16--14:02: _Comment on MedCrave...
- 11/05/16--14:19: _Comment on MedCrave...
- 11/05/16--14:36: _Comment on About Th...
- 11/04/16--10:08: Comment on Beall’s List of Predatory Publishers 2016 by Evans Gyan
- 11/05/16--09:45: Comment on Beall’s List of Predatory Publishers 2016 by Hala
I bet MedCrap people read this blog but the funny thing is I’m quite sure they can’t understand all the sarcasm going on.
RS Publication is included on my list. It's an extremely low-quality and amateurish publisher, and I strongly recommend that you <strong>not </strong>publish any articles in its journals.
Check out another hilariously bullet-to-foot attempt at defending MedCrave:
“The medical work and scientific content are peer reviewed by the Editor.”
I don’t think they know what “peer review” means…
No, I do not, sorry.
The <em>Business and Management Research Journal</em> is published by International Research Journals of Accra, Ghana. I have this publsiehr included on my <a href="https://scholarlyoa.com/publishers/" target="_blank">list </a>and recommend against submitting work to any of its journals.
Similarly, the <em>International Journal of Business Management and Administration</em> is from a predatory publisher called Academe Research Journals. This publisher is also on my list, so please avoid all its journals also.
Thank you very much for providing this service. It’s very helpful! I, too, get these emails and it’s good to know.
This is pathetic, their English is getting worse and worse.
[…] appear on the same cover of a 2011-2012 issue of the journal, as librarian Jeffrey Beall noted in a blog post published last year. But since then, there seems to have been an “academic split” between the two (as defined by […]
Its funny how these e-mails are sent during daytime hours in India and very late at night in the US where their headquarters supposedly are.
Both of these publishers:
MECS (Modern Education and Computer Science Press)
IRAJ (Institute of Research and Journals)
are on my list <a href="https://scholarlyoa.com/publishers/" target="_blank">here</a>. I recommend you avoid them.
May I know if IAMURE is a credible journal?
Our friend, Lisseth, is still at it on Nov 5.
Here is here latest.
Dear Dr. Morris,
My last email must have reached you at a bad time so I am following up. If you are not the right person to talk to about this please let me know or feel free to forward this email.
I am also including links to a couple of our recently published articles so you may have a sense of the style and formatting.
Current Technological State of Radiation Therapy for the Treatment of Lung Cancer
Longitudinal Follow-up Study of Bone Mineral Density in Adult Survivors of Solid Pediatric Cancers
Dr. Lisseth Tovar
In my opinion, IAMURE is a very low quality publisher. I recommend that you avoid it and find a stronger publisher for your work.
I wanted to ask about Diabetes metabolic syndrome and obesity:Targets and Therapy.
As someone told me it is not quite good and I couldn’t find anything against it.
Plus their publication fee is high.
Can you advise please
<em>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</em> is published by Dove Press. Although this publisher is not on my list at this time, I personally would never publish in any of its journals, and I would encourage my friends and colleagues to also bypass this publisher's journals. I recommend you find a stronger publisher for your work.
More and more I incline to the view that those Quora threads are satires, set up by someone who holds a grudge against MedCrave and is trying to hard to ensure that any search for “Medcrave” brings the searcher to the word “predatory”.
The same applies to the blog mentioned by Keith and Marco —
— it links to the Quora threads, and regularly reminds readers that “MedCrave Never Featured in Predatory Publishers List.”
It also refers readers to a companion blog with the same design
and an associated slide show
And a WordPress version as well:
which are all excuses to say “We deny and refute the accusations made against us, that we are predatory OMICS clones! We are a totally reputable above-board publisher, interested only in spreading information around, and by the way, those accusations against us, here they are again! Did we mention that accusations have been made against us?”.
Someone has had fun writing the blog posts in a tone of sustained tongue-in-cheek denial, and the same Indglish style as the Quora threads. If the author of the whole spoof is reading this, Bravo! And I apologise for my earlier criticisms.
Some of the blogposts include a Location:
It points to a corner of a field in Independence, Kansas. I suspect this to be an in-joke, known only to the pranksters. Someone has added a note to Google Maps that Sandy Garvin, Fine Art is located on that corner of a field, but this is implausible (since Sandy Garvin is also described as residing in Lyme, CT). There are shenanigans going on.
I got the spam(s), too. It is quite easy to understand what it is about (complete rubbish) because my research does not deal with medicine or even biology. I chose to reply with the text below, mostly for fun. Maybe I will get a reply. Who knows?
Dear Dr. Tovar,
this is very fortunate that you contact me now. We were about to submit our latest contribution together with Dr. M. Aboule, MD, with the title “Crushing glioblastoma in its early stage with bowling balls” to The Lancet. But I saw that we could spend 3000$ to publish in your journal, which seems very attractive. As you may know, we are overpaid and we cannot seem to get rid of the money our fantastic approach granted us. In fact, our treatment is very effective as we have never heard any complaint from our patients. Moreover, we developed a very fruitful partnership with a funeral home.